Pacific Biosciences of California, Inc. - Common Stock (NQ:PACB)

2.665 -0.035 (-1.30%)

Delayed Quote Updated: 10:42 AM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pacific Biosciences of California, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Cathie Wood's Buying These 3 Stocks Hand Over Fist ↗

September 08, 2023

A drugmaker, a gene sequencer, and a streaming business all made deep impressions on Ark Invest's stock-picking team.

Via The Motley Fool

Analyst Expectations for Pacific Biosciences's Future ↗

August 22, 2023

Via Benzinga

Rising Fuel Costs Lead To Win For Energy, Cathie Wood's Biotech Play Loses Big - ETF Winners And Losers: Medium-Cap Returns ↗

August 14, 2023

We performed a screening of medium-cap ETFs, defined as having Assets Under Management (AUM) between $2 billion and $10 billion - to determine what funds had the largest positive and negative returns...

Via Benzinga

Topics ETFs

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

August 09, 2023

The growth-focused money manager is making moves, with her ETFs beating the market again in 2023 after terrible returns the two previous years.

Via The Motley Fool

Palantir Post Q2 Earnings Share Price Dip Doesn't Deter Cathie Wood — Ark Invest Buys $14M Worth Of Shares ↗

August 08, 2023

Via Benzinga

The Latest Analyst Ratings for Pacific Biosciences ↗

August 03, 2023

Via Benzinga

Analyst Ratings for Pacific Biosciences ↗

June 30, 2023

Via Benzinga

Where Pacific Biosciences Stands With Analysts ↗

June 05, 2023

Via Benzinga

Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports ↗

August 07, 2023

Via Benzinga

PacBio and GeneDx Launch Research Collaboration with the University of Washington to Study Long-Read Whole Genome Sequencing for Increased Diagnostic Yield in Neonatal Care

August 07, 2023

Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms

From GeneDx Holdings Corp.; PacBio

Via GlobeNewswire

Cathie Wood's Ark Invest Acquires $5.5M of Robinhood Shares Following Platform's First Profitable Quarter ↗

August 03, 2023

Via Benzinga

Expert Ratings for Pacific Biosciences ↗

May 04, 2023

Via Benzinga

Pacific Biosciences (NASDAQ: PACB) Making Surprising Moves in Friday Session

March 31, 2023

Via Investor Brand Network

Earnings Scheduled For February 16, 2023 ↗

February 16, 2023

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...

Via Benzinga

Earnings Outlook For Pacific Biosciences ↗

February 15, 2023

Via Benzinga

Thoughts For Thursday: Back From The Holiday With Caution ↗

July 06, 2023

Caution is perhaps what was reflected in yesterday's back from the holiday trading. One there is the question of upcoming Fed action and second there is the visit of Secretary Yellen to China.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023 ↗

June 30, 2023

Via Benzinga

Market Mixes It Up With A Broad Rally ↗

June 05, 2023

Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive.

Via Talk Markets

Time To Play Small Cap Life Science Stocks ↗

May 15, 2023

The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling.

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023 ↗

May 10, 2023

Via Benzinga

Something Happened In Biotech Last Week ↗

May 08, 2023

Biotech stocks were more constructive last week with some sharp moves up.

Via Talk Markets

Cathie Wood Scoops Up AMD Stock On A Day When It Tanks Over 9%: Also Raises Stake In This Biotech Company ↗

May 03, 2023

Via Benzinga

Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector ↗

May 01, 2023

A pivotal week looks to be shaping up with the usual macro concerns arising, such as a Fed meeting and big earnings waiting just around the corner. One possible path to help navigate around these macro...

Via Talk Markets

Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday ↗

April 13, 2023

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Biotech And Life Science Trades: Q1 2023 Performance By The Numbers ↗

April 01, 2023

Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of...

Via Talk Markets

Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023 ↗

March 31, 2023

Via Benzinga

Rumble, TORM And Other Big Stocks Moving Higher In Friday's Pre-Market Session ↗

March 31, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

SMID Cap Life Science Update: Are You An Investor Or Trader? ↗

February 20, 2023

Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows.

Via Talk Markets

Why Bionano Genomics, Pacific Biosciences of California, and Sangamo Therapeutics Stocks Crumbled This Week ↗

February 10, 2023

These cutting-edge biotech companies quickly fell out of favor with investors this week.

Via The Motley Fool

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.